L2
L2T1.F LifeVantage Corporation
- Market cap
- EUR 56.6M
- P/E
- 24.8x
- P/B
- 1.70x
- ROE
- -2.4%
- Dividend yield
- 4.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is L2T1.F undervalued?
Graham numberL2T1.F trades 37.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LifeVantage Corporation fundamental analysis
No fundamental analysis for LifeVantage Corporation yet.
LifeVantage Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LifeVantage Corporation
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to s…
Full company profileLifeVantage Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LifeVantage Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 199M | 203M | 226M | 233M | 220M | 206M | 213M | 200M | 229M | 183M | 148M |
| Gross Profit | 166M | 168M | 188M | 195M | 182M | 168M | 170M | 159M | 184M | 142M | 112M |
| Operating Income | 4.45M | 10.3M | 9.81M | 15.5M | 17.6M | 7.58M | 4.26M | 4.33M | 12.2M | 6.10M | -544K |
| EBITDA | 5.11M | 11.3M | 11.4M | 19.9M | 23.1M | 9.75M | 7.84M | 7.91M | 15.4M | 8.87M | 2.38M |
| Net Income | 1.61M | 5.76M | 7.43M | 11.5M | 12.9M | 3.12M | 2.54M | 2.94M | 9.81M | 5.07M | -784K |
| EPS | 0.11 | 0.41 | 0.53 | 0.81 | 0.95 | 0.25 | 0.20 | 0.23 | 0.78 | 0.41 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 45.2M | 51.1M | 55.3M | 58.9M | 78.7M | 70.7M | 66.1M | 60.3M | 72.0M | 62.1M | 59.2M |
| Total Liabilities | 30.7M | 29.2M | 28.1M | 25.6M | 41.9M | 39.2M | 31.5M | 34.3M | 37.3M | 28.5M | 25.9M |
| Shareholders' Equity | 14.5M | 21.9M | 27.2M | 33.3M | 36.8M | 31.5M | 34.6M | 26.0M | 34.6M | 33.6M | 33.3M |
| Cash & Short-term Investments | 11.5M | 16.7M | 18.8M | 22.1M | 23.2M | 20.2M | 21.6M | 16.9M | 20.2M | 14.9M | 13.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 6.60M | 13.3M | 17.8M | 18.3M | 16.3M | 7.96M | 6.83M | 12.2M | 11.9M | 10.2M | 2.13M |
| Capital Expenditure | 1.06M | 4.65M | 2.51M | 2.68M | 3.74M | 1.53M | 3.07M | 2.25M | 1.37M | 3.57M | 4.96M |
| Free Cash Flow | 5.54M | 8.61M | 15.3M | 15.6M | 12.5M | 6.43M | 3.76M | 9.95M | 10.5M | 6.67M | -2.83M |
| Ratios | |||||||||||
| ROE | 11.1% | 26.2% | 27.3% | 34.7% | 35.0% | 9.9% | 7.3% | 11.3% | 28.3% | 15.1% | -2.4% |
| ROA | 3.6% | 11.3% | 13.4% | 19.6% | 16.4% | 4.4% | 3.8% | 4.9% | 13.6% | 8.2% | -1.3% |
| Net Profit Margin | 0.8% | 2.8% | 3.3% | 5.0% | 5.9% | 1.5% | 1.2% | 1.5% | 4.3% | 2.8% | -0.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
LifeVantage Corporation dividends
- Dividend yield
- 4.07%
- Forward dividend
- 0.17 EUR
- Payout ratio
- 46.2%
- Ex-dividend date
- Sep 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 2.34M | 0.19 | 46.2% |
| 2025 | USD 2.07M | 0.16 | 21.1% |
| 2024 | USD 6.94M | 0.55 | 236.3% |
| 2023 | USD 1.59M | 0.13 | 62.4% |
| 2022 | USD 378K | 0.03 | 12.1% |
| 2021 | USD 378K | 0.03 | 2.9% |
| 2020 | USD 378K | 0.03 | 3.3% |
| 2019 | USD 378K | 0.03 | 5.1% |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:7 on Oct 19, 2015.
Who owns LifeVantage Corporation
- Insiders 13.69%
- Institutions 56.40%
- Public & others 29.91%
- Shares outstanding 12.7M
- Free float 8.55M
LifeVantage Corporation company profile
- Company name
- LifeVantage Corporation
- Ticker
- L2T1.F
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 209
- Fiscal year end
- June
- Address
- 3300 North Triumph Boulevard, Lehi, UT, United States, 84043
- Phone
- 801 432 9000
- Website
- lifevantage.com
About LifeVantage Corporation
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, gut health, and skin and hair care products in the United States and internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM and Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; P84 System, a product activator consisting of PhytoPower 1 and PhytoPower 2 that contains probiotics, prebiotics, postbiotics, digestive enzymes, and superfood blends designed to support gut health; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. It also provides anti-aging skin care products, such as liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, and hand creams, as well as shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name. It sells its products through its website and network of independent consultants. LifeVantage Corporation is based in Lehi, Utah.
LifeVantage Corporation management
5- Mr. Carl A. Aure CPAChief Financial Officer · born 1973
- Ms. Kristen CunninghamChief Sales Officer · born 1984
- Mr. Terrence O. MooreheadPresident, CEO & Director · born 1963
- Mr. Mike EdwardsChief Technology Officer
- Ms. Michelle Oborn-VirchowChief People Officer · born 1980